J-aggregates albumin-based NIR-II fluorescent dye nanoparticles for cancer phototheranostics. (December 2022)
- Record Type:
- Journal Article
- Title:
- J-aggregates albumin-based NIR-II fluorescent dye nanoparticles for cancer phototheranostics. (December 2022)
- Main Title:
- J-aggregates albumin-based NIR-II fluorescent dye nanoparticles for cancer phototheranostics
- Authors:
- Du, Bulin
Liu, Ruiqi
Qu, Chunrong
Qian, Kun
Suo, Yongkuan
Wu, Fengxia
Chen, Hongda
Li, Xuena
Li, Yaming
Liu, Hongguang
Cheng, Zhen - Abstract:
- Abstract: Phototheranostics, relying on energy conversions of fluorophores upon excitation, integrating diagnostic fluorescence imaging and photo-driven therapy, represents a promising strategy for cancer precision medicine. Compared with the first near-infrared biological window (NIR-I), fluorophores imaged in the second window (NIR-II, 1000–1700 nm) exhibit a higher temporal and spatial resolution and tissue penetration depth. Polymethine cyanine-based dye IR1061 is a typical NIR-II small-molecule organic fluorophore, but its low water solubility and short circulation time limiting its biological applications. Therefore, human serum albumin (HSA) nanoparticles with great biocompatibility and biosafety were employed to fabricate hydrophobic IR1061, which exhibited red-shifted absorption band as typical for J-aggregates. Moreover, IR1061@HSA nanoparticles can be successfully used for NIR-II imaging to noninvasively visualize the tumor vascular networks, as well as real-time intraoperative image-guided tumor resection. Interestingly, benefiting from the high photothermal conversion efficiency brought by J-aggregates, IR1061@HSA nanoparticles were also explored for photothermal therapy (PTT) and cause efficient thermal ablation of tumors. Overall, IR1061@HSA, as a novel J-aggregates albumin-based NIR II dye nanoparticle with high biocompatibility, provides an integrated versatile platform for cancer phototheranostics with promising clinical translation prospects. GraphicalAbstract: Phototheranostics, relying on energy conversions of fluorophores upon excitation, integrating diagnostic fluorescence imaging and photo-driven therapy, represents a promising strategy for cancer precision medicine. Compared with the first near-infrared biological window (NIR-I), fluorophores imaged in the second window (NIR-II, 1000–1700 nm) exhibit a higher temporal and spatial resolution and tissue penetration depth. Polymethine cyanine-based dye IR1061 is a typical NIR-II small-molecule organic fluorophore, but its low water solubility and short circulation time limiting its biological applications. Therefore, human serum albumin (HSA) nanoparticles with great biocompatibility and biosafety were employed to fabricate hydrophobic IR1061, which exhibited red-shifted absorption band as typical for J-aggregates. Moreover, IR1061@HSA nanoparticles can be successfully used for NIR-II imaging to noninvasively visualize the tumor vascular networks, as well as real-time intraoperative image-guided tumor resection. Interestingly, benefiting from the high photothermal conversion efficiency brought by J-aggregates, IR1061@HSA nanoparticles were also explored for photothermal therapy (PTT) and cause efficient thermal ablation of tumors. Overall, IR1061@HSA, as a novel J-aggregates albumin-based NIR II dye nanoparticle with high biocompatibility, provides an integrated versatile platform for cancer phototheranostics with promising clinical translation prospects. Graphical abstract: The novel J-aggregates IR1061@HSA nanoparticles have been successfully developed and effectively used for in vivo NIR-II imaging to noninvasively visualize and monitor the tumor vascular networks, as well as real-time NIR-II image-guided intraoperative tumor resection. Moreover, IR1061@HSA nanoparticles have a strong photothermal conversion effect and could thus be an ideal photothermal agent for cancer PTT. Overall, IR1061@HSA, as an albumin-based NIR II dye nanoparticle with high biocompatibility, provides an integrated versatile platform for cancer phototheranostics with promising clinical translation prospects. Image 1 … (more)
- Is Part Of:
- Materials today bio. Volume 16(2022)
- Journal:
- Materials today bio
- Issue:
- Volume 16(2022)
- Issue Display:
- Volume 16, Issue 2022 (2022)
- Year:
- 2022
- Volume:
- 16
- Issue:
- 2022
- Issue Sort Value:
- 2022-0016-2022-0000
- Page Start:
- Page End:
- Publication Date:
- 2022-12
- Subjects:
- IR1061 -- Human serum albumin -- Nanoparticles -- Second near-infrared window -- Fluorescence imaging -- Photothermal therapy
Materials science -- Periodicals
Biomedical engineering -- Periodicals
Biomedical materials -- Periodicals
620.1 - Journal URLs:
- https://www.sciencedirect.com/journal/materials-today-bio ↗
http://www.sciencedirect.com/ ↗ - DOI:
- 10.1016/j.mtbio.2022.100366 ↗
- Languages:
- English
- ISSNs:
- 2590-0064
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 24121.xml